Craft

EKF Diagnostics

Stock Price

£0.3

2024-10-29

Market Capitalization

£121.1 M

2024-10-29

Revenue

£51.6 M

FY, 2025

EKF Diagnostics Summary

Company Summary

Overview
EKF Diagnostics Holdings is a company that manufactures point-of-care (POCT) devices and tests for hemoglobin, glycated hemoglobin (HbA1c), glucose, and lactate. Its products serve in blood banks, general practitioners (GP) surgeries, diabetes clinics, pharmacies, sports medicine, emergency rooms, and laboratories. The company also produces clinical chemistry reagents and distributes Kantaro COVID-SeroKlir antibody kits.
Type
Public
Status
Active
Founded
1990
HQ
Penarth, GB | view all locations
Website
https://www.ekfdiagnostics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Mike Salter
  • Julian Baines

    Julian Baines, Executive Chairman

  • Christopher Mills

    Christopher Mills, Non-Executive Director

    • Jennifer Winter

      Jennifer Winter, Non-Executive Director

    LocationsView all

    6 locations detected

    • Penarth HQ

      United Kingdom

      Avon House 19 Stanwell Rd

    • Boerne, TX

      United States

      1261 N Main St

    • Elkhart, IN

      United States

      1814 Leer Dr

    • Shanghai, Shanghai Shi

      China

      Suite 1202, Jin Hong Qiao International Center Building I, No. 523, Loushan-guan Road, Changning District

    • Barleben, SA

      Germany

      Ebendorfer Ch 3

    • Leipzig, SN

      Germany

      Bautzner Str. 67

    EKF Diagnostics Financials

    Summary Financials

    Revenue (FY, 2025)
    £51.6M
    Gross profit (FY, 2025)
    £32.1M
    Net income (FY, 2025)
    £2.5M
    Cash (FY, 2025)
    £15.8M
    EBIT (FY, 2025)
    £7.2M
    Enterprise value
    $106.7M

    Footer menu